INCYHealthcare · BiotechnologyThe 27 Wall Street analysts covering Incyte Corp. hold a median 12-month price target of $120 — -0.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 15 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Incyte Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (46): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INCY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −0.1% from it.
Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Mizuho | Maintains | Outperform | $121 → $137 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $150 |
| 3 Aug 2026 | Leerink Partners | Maintains | Outperform | $131 → $155 |
| 29 July 2026 | Barclays | Maintains | Overweight | $134 → $139 |
| 29 July 2026 | BMO Capital | Maintains | Market Perform | $112 → $130 |
| 29 July 2026 | Guggenheim | Maintains | Buy | $136 → $150 |
| 29 July 2026 | HC Wainwright & Co. | Maintains | Buy | $140 → $150 |
| 29 July 2026 | RBC Capital | Maintains | Sector Perform | $99 → $109 |
| 23 July 2026 | JP Morgan | Maintains | Neutral | $105 → $110 |
| 23 July 2026 | JP Morgan | Maintains | Neutral | — |
| 23 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 23 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $103 → $104 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $140 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 July 2026 | Barclays | Maintains | Overweight | — |
| 14 July 2026 | Barclays | Maintains | Overweight | $117 → $134 |
| 13 July 2026 | BMO Capital | Maintains | Market Perform | $94 → $112 |
| 13 July 2026 | BMO Capital | Maintains | Market Perform | — |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | $95 → $99 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INCY appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 47% of US stocks
Cheaper than 31% of US stocks
Cheaper than 28% of US stocks
Cheaper than 38% of US stocks
Higher than 82% of US stocks
Higher than 73% of US stocks
Higher than 98% of US stocks
Higher than 93% of US stocks
Higher than 87% of US stocks
Higher than 88% of US stocks
Higher than 98% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Incyte Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Incyte Corporation has received backing from large institutional investors, and its share price has risen 23% so far in 2026. The gains are attributed to sales growth.
Why it matters — A strong 23% share-price gain driven by sales growth indicates improving commercial performance for Incyte in 2026.
Incyte Corp. announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The release, issued via Business Wire from Wilmington, Delaware, reports equity awards made as an inducement for new employees.
Why it matters — Incyte watchers would care because this is a routine disclosure of equity compensation grants tied to hiring, which affects share counts and compensation practices.
Zacks Investment Research compares Regeneron (REGN) and Incyte (INCY) as potential value-stock picks within the Medical - Biomedical and Genetics sector, evaluating which of the two is more attractive to value investors.
Why it matters — INCY watchers would care because the article directly assesses Incyte's appeal as a value investment relative to a sector peer.
Zacks Investment Research highlighted Incyte (INCY) as a strong momentum stock through its Style Scores system, which helps investors identify top-rated stocks based on investing style.
Why it matters — INCY watchers would care because a strong momentum designation from Zacks could attract attention from momentum-focused investors, potentially influencing near-term trading activity in the stock.
Incyte reported better-than-expected second-quarter results and raised its full-year sales guidance, leading analysts to raise their forecasts.
Why it matters — Improved quarterly performance and raised full-year guidance point to stronger business momentum, which INCY watchers would monitor for future earnings quality.
The 27 Wall Street analysts covering Incyte Corp. have a median 12-month price target of $120, with estimates ranging from $86 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Incyte Corp., 11 rate it a Buy, 15 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Incyte Corp. 90 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Incyte Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies -0.1% from the last close, and Ticker Nerd's factor model ranks Incyte Corp. 90 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Incyte Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $155 over the next 12 months.
Incyte Corp. returned +39.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates on hematology and oncology, as well as inflammation, autoimmunity, and dermatology, addressing diseases with significant unmet medical needs.
The most recent item we track (FXEmpire, 12 Aug 2026): "Incyte Sales Growth Drives Share Price Gains". Incyte Corporation has received backing from large institutional investors, and its share price has risen 23% so far in 2026. The gains are attributed to sales growth.
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates on hematology and oncology, as well as inflammation, autoimmunity, and dermatology, addressing diseases with significant unmet medical needs. A core part of its business is small-molecule drug development, supported by a broad pipeline of oncology and dermatology programs. Incyte’s portfolio includes Jakafi for certain rare blood cancers and graft-versus-host disease, along with partnered and licensed therapies such as Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. The company also markets Opzelura, a topical treatment for atopic dermatitis and vitiligo in dermatology. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte plays a notable role in the healthcare and biotechnology sectors by providing targeted therapies that are integrated into specialized care across global markets.
CEO Mr. William J. Meury · 2,844 employees · United States · https://www.incyte.com